Long-term outcome of percutaneous or surgical revascularization with and without prior stroke in patients with three-vessel disease

Na XU; Ce ZHANG; Lin JIANG; Jing-Jing XU; Ru LIU; Ying SONG; Xue-Yan ZHAO; Lian-Jun XU; Run-Lin GAO; Bo XU; Jin-Qing YUAN; Lei SONG

doi:10.11909/j.issn.1671-5411.2022.08.001

Volume 19 Issue 8

Aug. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2022 > 19(8): 583-593

Na XU, Ce ZHANG, Lin JIANG, Jing-Jing XU, Ru LIU, Ying SONG, Xue-Yan ZHAO, Lian-Jun XU, Run-Lin GAO, Bo XU, Jin-Qing YUAN, Lei SONG. Long-term outcome of percutaneous or surgical revascularization with and without prior stroke in patients with three-vessel disease. J Geriatr Cardiol 2022; 19(8): 583-593. doi: 10.11909/j.issn.1671-5411.2022.08.001

Citation:

Na XU, Ce ZHANG, Lin JIANG, Jing-Jing XU, Ru LIU, Ying SONG, Xue-Yan ZHAO, Lian-Jun XU, Run-Lin GAO, Bo XU, Jin-Qing YUAN, Lei SONG. Long-term outcome of percutaneous or surgical revascularization with and without prior stroke in patients with three-vessel disease. J Geriatr Cardiol 2022; 19(8): 583-593. doi: 10.11909/j.issn.1671-5411.2022.08.001

Citation:

Na XU, Ce ZHANG, Lin JIANG, Jing-Jing XU, Ru LIU, Ying SONG, Xue-Yan ZHAO, Lian-Jun XU, Run-Lin GAO, Bo XU, Jin-Qing YUAN, Lei SONG. Long-term outcome of percutaneous or surgical revascularization with and without prior stroke in patients with three-vessel disease. J Geriatr Cardiol 2022; 19(8): 583-593. doi: 10.11909/j.issn.1671-5411.2022.08.001

PDF( 6702 KB)

Long-term outcome of percutaneous or surgical revascularization with and without prior stroke in patients with three-vessel disease

doi: 10.11909/j.issn.1671-5411.2022.08.001

1.
Center for Coronary Heart Disease, National Clinical Research Center for Cardiovascular Diseases, National Center for Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

More Information

Corresponding author: dr_jinqingyuan@sina.com; songlqd@126.com
Available Online: 2022-07-29
Publish Date: 2022-08-28

Abstract

Abstract

OBJECTIVE To determine whether high-risk patients with three-vessel disease (TVD) with and without prior stroke preferentially benefit from three strategies [percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG) and medical therapy (MT)]. METHODS A total of 8943 patients with TVD were included in the study. Patients enrolled were stratified into two categories according to the presence or absence of prior stroke history. The primary endpoint was all-cause death. Secondary endpoints included stroke and major adverse cardiac and cerebrovascular event (MACCE), a composite of death, myocardial infarction (MI), unplanned revascularization and stroke. RESULTS Prior stroke was present in 888 patients (9.9%). These patients were older and had higher rates of comorbidities. During a median follow-up of 7.5 years, patients with prior stroke were strongly associated with increased risks of all-cause death, cardiac death, stroke and MACCE, even after adjusting for confounding variables and results been consistent across either treatment subgroup (PCI, CABG and MT) (all adjusted P < 0.01). Notably, there was a significant interaction between prior stroke history and treatment strategies. Revascularization strategy (PCI or CABG) was associated with a lower incidence of all-cause death and MACCE compared with MT alone, and favorable rates of MACCE, MI and unplanned revascularization in the CABG group compared with the PCI group, but with similar rate of all-cause death regardless of prior stroke history. The prevalence of stroke was significantly higher after CABG when compared with PCI or MT in no prior stroke patients [hazard ratio (HR) = 1.429, 95% CI: 1.132–1.805 for CABG vs. MT; HR = 1.703, 95% CI: 1.371–2.116 for CABG vs. PCI]. CONCLUSIONS Patients with TVD and prior stroke have poor clinical outcomes. It is essential to balance benefit and risk when determining the optimal treatment strategy for TVD with and without prior stroke.

FullText(HTML)

References(22)

References

[1]	Gorelick PB. Epidemiology of transient ischemic attack and ischemic stroke in patients with underlying cardiovascular disease. Clin Cardiol 2004; 27: II4−II11. doi: 10.1002/clc.4960271403
[2]	Ducrocq G, Amarenco P, Labreuche J, et al. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation 2013; 127: 730−738. doi: 10.1161/CIRCULATIONAHA.112.141572
[3]	Bhatt DL, Peterson ED, Harrington RA, et al. Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J 2009; 30: 1195−1202. doi: 10.1093/eurheartj/ehp099
[4]	Song C, Sukul D, Seth M, et al. Outcomes after percutaneous coronary intervention in patients with a history of cerebrovascular disease: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Circ Cardiovasc Interv 2018; 11: e006400. doi: 10.1161/CIRCINTERVENTIONS.118.006400
[5]	Xu JJ, Song Y, Jiang P, et al. Effect of prior stroke on long-term outcomes of percutaneous coronary interventions in Chinese patients: a large single-center study. Catheter Cardiovasc Interv 2019; 93: E75−E80. doi: 10.1002/ccd.27705
[6]	Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011; 32: 2125−2134. doi: 10.1093/eurheartj/ehr213
[7]	Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381: 629−638. doi: 10.1016/S0140-6736(13)60141-5
[8]	Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009; 373: 1190−1197. doi: 10.1016/S0140-6736(09)60552-3
[9]	Palmerini T, Biondi-Zoccai G, Reggiani LB, et al. Risk of stroke with coronary artery bypass graft surgery compared with percutaneous coronary intervention. J Am Coll Cardiol 2012; 60: 798−805. doi: 10.1016/j.jacc.2011.10.912
[10]	Head SJ, Milojevic M, Daemen J, et al. Stroke rates following surgical versus percutaneous coronary revascularization. J Am Coll Cardiol 2018; 72: 386−398. doi: 10.1016/j.jacc.2018.04.071
[11]	Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44−e122. doi: 10.1016/j.jacc.2011.08.007
[12]	Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 58: e123−e210. doi: 10.1016/j.jacc.2011.08.009
[13]	Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013; 44: 2064−2089. doi: 10.1161/STR.0b013e318296aeca
[14]	Taylor J. Third universal definition of myocardial infarction. Eur Heart J 2012; 33: 2506−2507. doi: 10.1093/eurheartj/ehs296
[15]	Diamond J, Madhavan MV, Sabik JF 3rd, et al. Left main percutaneous coronary intervention versus coronary artery bypass grafting in patients with prior cerebrovascular disease: results from the EXCEL trial. JACC Cardiovasc Interv 2018; 11: 2441−2450. doi: 10.1016/j.jcin.2018.09.008
[16]	Wang R, Takahashi K, Garg S, et al. Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study. Clin Res Cardiol 2021; 110: 1543−1553. doi: 10.1007/s00392-020-01802-x
[17]	Hueb W, Lopes N, Gersh BJ, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010; 122: 949−957. doi: 10.1161/CIRCULATIONAHA.109.911669
[18]	Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375−2384. doi: 10.1056/NEJMoa1211585
[19]	Heldner MR, Li L, Lovett NG, et al. Long-term prognosis of patients with transient ischemic attack or stroke and symptomatic vascular disease in multiple arterial beds. Stroke 2018; 49: 1639−1646. doi: 10.1161/STROKEAHA.118.020913
[20]	Gaudino M, Angiolillo DJ, Di Franco A, et al. Stroke after coronary artery bypass grafting and percutaneous coronary intervention: incidence, pathogenesis, and outcomes. J Am Heart Assoc 2019; 8: e013032. doi: 10.1161/JAHA.119.013032
[21]	Palmerini T, Biondi-Zoccai G, Riva DD, et al. Risk of stroke with percutaneous coronary intervention compared with on-pump and off-pump coronary artery bypass graft surgery: evidence from a comprehensive network meta-analysis. Am Heart J 2013; 165: 910−917. doi: 10.1016/j.ahj.2013.03.011
[22]	Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45: 2160−2236. doi: 10.1161/STR.0000000000000024